GENEXPLAIN GMBH

Their core work

geneXplain is a German bioinformatics SME that develops computational tools and platforms for analyzing biological data — particularly gene regulation, pathway analysis, and disease modeling. They apply systems biology and multi-omics approaches to understand disease mechanisms at the molecular level, with a focus on cancer and neurodegeneration. Their core value lies in translating complex genomic and transcriptomic data into actionable insights for precision medicine, working as the computational analysis partner within large biomedical research consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), geneXplain contributed to diverse biomedical projects including biophotonic diagnostics, optogenetic therapy, and glioblastoma training networks — suggesting a broad bioinformatics service role. From 2018 onward, their work sharpened toward precision medicine, with COLOSSUS and PD-MitoQUANT showing deep engagement in multi-omics patient stratification and quantitative disease characterization. The keyword data confirms this shift: all specific technical terms (multi-omics, immunomics, systems medicine, computational models) appear only in the later projects.

geneXplain is moving from general bioinformatics service provision toward specialized computational precision medicine, particularly in cancer stratification and neurodegenerative disease modeling.

How they like to work

geneXplain operates exclusively as a participant — they have never coordinated an H2020 project, which is typical for a specialist SME that provides computational expertise within larger consortia. With 57 unique partners across 15 countries in just 5 projects, they work in large, internationally diverse consortia (averaging 11+ partners per project). This pattern indicates they are a trusted specialist brought in for specific analytical capabilities rather than a project driver.

geneXplain has collaborated with 57 distinct partners across 15 countries through 5 projects, giving them a broad European network concentrated in biomedical research. Their consortia span universities, research hospitals, and pharma companies across Western and Southern Europe.

What sets them apart

geneXplain occupies a niche as a private-sector computational biology company that bridges the gap between raw omics data and clinical decision-making. Unlike academic bioinformatics groups, they bring commercial software platforms and reproducible analysis pipelines to consortia. For consortium builders, they offer a rare combination: an SME with deep expertise in gene regulatory network analysis and disease pathway modeling, packaged for integration into translational medicine projects.

Highlights from their portfolio

• COLOSSUS
  Largest funding (EUR 281,865) and most technically rich project, combining multi-omics, immunomics, and computational models for colorectal cancer patient stratification.
• OPTOGENERAPY
  Highest single-project funding (EUR 386,100) and an unusual intersection of optogenetics and protein therapy for multiple sclerosis.
• PD-MitoQUANT
  Represents their most recent direction — quantitative mitochondrial characterization in Parkinson's disease, signaling deeper commitment to neurodegeneration research.